{"id":"silver","rwe":[],"_fda":{"id":"f63c800f-63a1-498e-9814-28b41de0c3b2","set_id":"0084786a-09a3-4612-9afc-6733cc0cc56a","openfda":{"nui":["N0000175503","M0020790"],"unii":["W46JY43EJR"],"route":["TOPICAL"],"rxcui":["106351"],"spl_id":["f63c800f-63a1-498e-9814-28b41de0c3b2"],"brand_name":["Silver Sulfadiazine"],"spl_set_id":["0084786a-09a3-4612-9afc-6733cc0cc56a"],"package_ndc":["63629-8773-1"],"product_ndc":["63629-8773"],"generic_name":["SILVER SULFADIAZINE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Sulfonamides [CS]"],"substance_name":["SILVER SULFADIAZINE"],"pharm_class_epc":["Sulfonamide Antibacterial [EPC]"],"manufacturer_name":["Bryant Ranch Prepack"],"application_number":["NDA018810"],"original_packager_product_ndc":["67877-124"]},"version":"105","warnings":["WARNINGS Absorption of silver sulfadiazine varies depending upon the percent of body surface area and the extent of the tissue damage. Although few have been reported, it is possible that any adverse reaction associated with sulfonamides may occur. Some of the reactions which have been associated with sulfonamides are as follows: blood dyscrasias including agranulocytosis, aplastic anemia, thrombocytopenia, leukopenia, and hemolytic anemia; dermatologic and allergic reactions, including life-threatening cutaneous reactions [Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and exfoliative dermatitis]; gastrointestinal reactions, hepatitis and hepatocellular necrosis; CNS reactions; and toxic nephrosis. There is a potential cross-sensitivity between silver sulfadiazine and other sulfonamides. If allergic reactions attributable to treatment with silver sulfadiazine occur, continuation of therapy must be weighed against the potential hazards of the particular allergic reaction. Fungal proliferation in and below the eschar may occur. However, the incidence of clinically reported fungal superinfection is low. The use of silver sulfadiazine cream, USP 1% in some cases of glucose-6-phosphate dehydrogenase-deficient individuals may be hazardous, as hemolysis may occur."],"pregnancy":["PREGNANCY: TERATOGENIC EFFECTS: Pregnancy Category B. A reproductive study has been performed in rabbits at doses up to three to ten times the concentration of silver sulfadiazine in silver sulfadiazine cream, USP 1% and has revealed no evidence of harm to the fetus due to silver sulfadiazine. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly justified, especially in pregnant women approaching or at term. (See CONTRAINDICATIONS )"],"references":["REFERENCES Caffee F, Bingham H. Leukopenia and silver sulfadiazine. J Trauma. 1982;22: 586–587. Jarret F, Ellerbe S, Demling R. Acute leukopenia during topical burn therapy with silver sulfadiazine. Amer J Surg. 1978;135: 818–819. Kiker RG, Carvajal HF, Micak RP, Larson DL. A controlled study of the effects of silver sulfadiazine on white blood cell counts in burned children. J Trauma. 1977;17: 835–836."],"description":["DESCRIPTION Silver sulfadiazine cream, USP 1% is a soft, white, water dispersible cream containing the antimicrobial agent silver sulfadiazine in micronized form for topical application. Each gram of silver sulfadiazine cream contains 10mg of micronized silver sulfadiazine. This active agent has the following structural formula: Silver sulfadiazine cream contains 1% w/w silver sulfadiazine. The vehicle in which the active ingredient is dispersed consists of water, stearyl alcohol, white petrolatum, polyoxyl 40 stearate, propylene glycol, isopropyl myristate, and sorbitan monooleate with 0.3% methylparaben as a preservative."],"precautions":["PRECAUTIONS General. If hepatic and renal functions become impaired and elimination of the drug decreases accumulation may occur. Discontinuation of silver sulfadiazine cream, USP 1% should be weighed against the therapeutic benefit being achieved. In considering the use of topical proteolytic enzymes in conjunction with Silver sulfadiazine cream, USP 1% the possibility should be noted that silver may inactivate such enzymes. Laboratory Tests. In the treatment of burn wounds involving extensive areas of the body, the serum sulfa concentrations may approach adult therapeutic levels (8 to 12mg %). Therefore, in these patients it would be advisable to monitor serum sulfa concentrations. Renal function should be carefully monitored and the urine should be checked for sulfa crystals. Absorption of the propylene glycol vehicle has been reported to affect serum osmolality, which may affect the interpretation of laboratory tests. Carcinogenesis, Mutagenesis, Impairment of Fertility. Long-term dermal toxicity studies of 24 months duration in rats and 18 months in mice with concentrations of silver sulfadiazine three to ten times the concentration in silver sulfadiazine cream, USP 1% revealed no evidence of carcinogenicity."],"how_supplied":["HOW SUPPLIED Silver sulfadiazine cream, USP 1% - white to off-white cream NDC Number Size 63629-8773-1 400g jar Store at room temperature. 15°-30°C (59°-86°F). Repackaged/Relabeled by: Bryant Ranch Prepack, Inc. Burbank, CA 91504"],"geriatric_use":["Geriatric Use. Of the total number of subjects in clinical studies of silver sulfadiazine cream, USP 1% seven percent were 65 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out."],"pediatric_use":["Pediatric Use. Safety and effectiveness in children have not been established. (See CONTRAINDICATIONS )"],"effective_time":"20250210","nursing_mothers":["Nursing Mothers. It is not known whether silver sulfadiazine cream, USP 1% is excreted in human milk. However, sulfonamides are known to be excreted in human milk and all sulfonamides derivatives are known to increase the possibility of kernicterus. Because of the possibility for serious adverse reactions in nursing infants from sulfonamides, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother."],"adverse_reactions":["ADVERSE REACTIONS Several cases of transient leukopenia have been reported in patients receiving silver sulfadiazine therapy. 1,2,3 Leukopenia associated with silver sulfadiazine administration is primarily characterized by decreased neutrophil count. Maximal white blood cell depression occurs within two to four days of initiation of therapy. Rebound to normal leukocyte levels follows onset within two to three days. Recovery is not influenced by continuation of silver sulfadiazine therapy. An increased incidence has been seen in patients treated concurrently with cimetidine. Other infrequently occurring events include skin necrosis, erythema multiforme, skin discoloration, burning sensation, rashes, and interstitial nephritis. Reduction in bacterial growth after application of topical antibacterial agents has been reported to permit spontaneous healing of deep partial-thickness burns by preventing conversion of the partial thickness to full thickness by sepsis. However, reduction in bacterial colonization has caused delayed separation, in some cases necessitating escharotomy in order to prevent contracture."],"contraindications":["CONTRAINDICATIONS Silver sulfadiazine cream, USP 1% is contraindicated in patients who are hypersensitive to silver sulfadiazine or any of the other ingredients in the preparation. Because sulfonamide therapy is known to increase the possibility of kernicterus, silver sulfadiazine cream, USP 1% should not be used on pregnant women approaching or at term, on premature infants, or on newborn infants during the first 2 months of life."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Silver sulfadiazine has broad antimicrobial activity. It is bactericidal for many gram-negative and gram-positive bacteria as well as being effective against yeast. Results from in vitro testing are listed below. Sufficient data have been obtained to demonstrate that silver sulfadiazine will inhibit bacteria that are resistant to other antimicrobial agents and that the compound is superior to sulfadiazine. Studies utilizing radioactive micronized silver sulfadiazine, electron microscopy, and biochemical techniques have revealed that the mechanism of action of silver sulfadiazine on bacteria differs from silver nitrate and sodium sulfadiazine. Silver sulfadiazine acts only on the cell membrane and cell wall to produce its bactericidal effect. Results of in Vitro Testing With Silver Sulfadiazine Cream, USP 1% Concentration of Silver Sulfadiazine Number of Sensitive Strains / Total Number of Strains Tested Genus and Species 50 µg/mL 100 µg/mL Pseudomonas aeruginosa 130/130 130/130 Xanthomonas (Pseudomonas) Maltophilia 7/7 7/7 Enterobacter species 48/50 50/50 Enterobacter cloacae 24/24 24/24 Klebsiella species 53/54 54/54 Escherichia coli 63/63 63/63 Serratia species 27/28 28/28 Proteus mirabilis 53/53 53/53 Morganella morganii 10/10 10/10 Providencia rettgeri 2/2 2/2 Proteus vulgaris 2/2 2/2 Providencia species 1/1 1/1 Citrobacter species 10/10 10/10 Acinetobacter calcoaceticus 10/11 11/11 Stahylococcus aureus 100/101 100/101 Staphylococcus epidermidis 51/51 51/51 β-Hemolytic Streptococcus 4/4 4/4 Enterococcus species 52/53 52/53 Corynebacterium diphtheriae 2/2 2/2 Clostridium perfringens 0/2 2/2 Candida albicans 43/50 50/50 Silver sulfadiazine is not a carbonic anhydrase inhibitor and may be useful in situations where such agents are contraindicated."],"indications_and_usage":["INDICATIONS AND USAGE Silver sulfadiazine cream, USP 1% is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns."],"spl_unclassified_section":[""],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Prompt institution of appropriate regimens for care of the burned patient is of prime importance and includes the control of shock and pain. The burn wounds are then cleansed and debrided; silver sulfadiazine cream, USP 1% is then applied under sterile conditions. The burn areas should be covered with silver sulfadiazine cream, USP 1% at all times. The cream should be applied once to twice daily to a thickness of approximately one sixteenth of an inch. Whenever necessary, the cream should be reapplied to any areas from which it has been removed by patient activity. Administration may be accomplished in minimal time because dressings are not required. However, if individual patient requirements make dressings necessary, they may be used. Reapply immediately after hydrotherapy. Treatment with silver sulfadiazine cream, USP 1% should be continued until satisfactory healing has occurred or until the burn site is ready for grafting. The drug should not be withdrawn from the therapeutic regimen while there remains the possibility of infection except if a significant adverse reaction occurs."],"spl_product_data_elements":["Silver Sulfadiazine Silver Sulfadiazine SILVER SULFADIAZINE SULFADIAZINE WATER STEARYL ALCOHOL PETROLATUM POLYOXYL 40 STEARATE PROPYLENE GLYCOL ISOPROPYL MYRISTATE SORBITAN MONOOLEATE METHYLPARABEN Ascend Title Structural Formula"],"clinical_pharmacology_table":["
Results of in Vitro Testing With Silver Sulfadiazine Cream, USP 1% Concentration of Silver Sulfadiazine Number of Sensitive Strains / Total Number of Strains Tested
Genus and Species50 µg/mL100 µg/mL
Pseudomonas aeruginosa130/130130/130
Xanthomonas (Pseudomonas) Maltophilia7/77/7
Enterobacter species48/5050/50
Enterobacter cloacae24/2424/24
Klebsiella species53/5454/54
Escherichia coli63/6363/63
Serratia species27/2828/28
Proteus mirabilis53/5353/53
Morganella morganii10/1010/10
Providencia rettgeri2/22/2
Proteus vulgaris2/22/2
Providencia species1/11/1
Citrobacter species10/1010/10
Acinetobacter calcoaceticus10/1111/11
Stahylococcus aureus100/101100/101
Staphylococcus epidermidis51/5151/51
β-Hemolytic Streptococcus4/44/4
Enterococcus species52/5352/53
Corynebacterium diphtheriae2/22/2
Clostridium perfringens0/22/2
Candida albicans43/5050/50
"],"package_label_principal_display_panel":["Silver Sulfadiazine Cream 1% #400 (Jar) Label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility. Long-term dermal toxicity studies of 24 months duration in rats and 18 months in mice with concentrations of silver sulfadiazine three to ten times the concentration in silver sulfadiazine cream, USP 1% revealed no evidence of carcinogenicity."]},"tags":[{"label":"Sulfonamide Antibacterial [EPC]","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Topical","category":"route"},{"label":"Cream","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"second degree burns","category":"indication"},{"label":"third degree burns","category":"indication"},{"label":"wound sepsis","category":"indication"},{"label":"King Pharms Llc","category":"company"},{"label":"Approved 1990s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"217 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"213 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"188 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"188 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"174 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"173 reports"},{"date":"","signal":"PRODUCT USE IN UNAPPROVED INDICATION","source":"FDA FAERS","actionTaken":"149 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"146 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"140 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"127 reports"}],"commonSideEffects":[{"effect":"Leukopenia","drugRate":"reported","severity":"unknown"},{"effect":"Skin necrosis","drugRate":"reported","severity":"unknown"},{"effect":"Erythema multiforme","drugRate":"reported","severity":"unknown"},{"effect":"Skin discoloration","drugRate":"reported","severity":"unknown"},{"effect":"Burning sensation","drugRate":"reported","severity":"unknown"},{"effect":"Rashes","drugRate":"reported","severity":"unknown"},{"effect":"Interstitial nephritis","drugRate":"reported","severity":"unknown"},{"effect":"Delayed separation","drugRate":"reported","severity":"unknown"}],"contraindications":["hypersensitivity to silver sulfadiazine","hypersensitivity to other ingredients","pregnant women approaching or at term","premature infants","newborn infants during the first 2 months of life"],"specialPopulations":{"Pregnancy":"Pregnancy Category B. A reproductive study has been performed in rabbits at doses up to three to ten times the concentration of silver sulfadiazine in silver sulfadiazine cream, USP 1% and has revealed no evidence of harm to the fetus due to silver sulfadiazine. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only when clearly needed.","Geriatric use":"Of the total number of subjects in clinical studies of silver sulfadiazine cream, USP 1% seven percent were 65 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.","Paediatric use":"Safety and effectiveness in children have not been established. (See CONTRAINDICATIONS )"}},"trials":[],"aliases":[],"company":"King Pharms Llc","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=SILVER","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:11:42.361823+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:11:47.366970+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:11:41.208637+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SILVER","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:11:47.790765+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:11:36.219072+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:11:36.219110+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:11:36.219117+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:11:49.489697+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL177367/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:11:48.670583+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA018810","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:11:36.219121+00:00"}},"allNames":"silver sulfadiazine","offLabel":[],"synonyms":["Silver Sulfadiazine","SILVER SULFADIAZINE"],"timeline":[{"date":"1982-02-25","type":"positive","source":"FDA Orange Book","milestone":"Ssd approved — 1%"},{"date":"1985-12-23","type":"positive","source":"FDA Orange Book","milestone":"Thermazene approved — 1%"},{"date":"1989-11-30","type":"positive","source":"FDA Orange Book","milestone":"Sildaflo approved — 1%"},{"date":"1990-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from Thepharmanetwork Llc to King Pharms Llc"},{"date":"19900510","type":"positive","source":"OpenFDA","milestone":"FDA approval (Thepharmanetwork Llc)"}],"approvals":[{"date":"19900510","orphan":false,"company":"THEPHARMANETWORK LLC","regulator":"FDA"}],"brandName":"Silver Sulfadiazine","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"Sulfonamide Antibacterial [EPC]","explanation":"","oneSentence":"","technicalDetail":"Silver Sulfadiazine is a sulfonamide antibacterial that exerts its antimicrobial effects through the release of silver ions, which disrupt bacterial cell membranes and inhibit DNA replication, ultimately leading to bacterial death."},"commercial":{"launchDate":"1990","_launchSource":"OpenFDA (19900510, THEPHARMANETWORK LLC)"},"references":[{"id":1,"url":"https://api.fda.gov/drug/label.json?search=openfda.generic_name:\"SILVER\"","fields":["mechanism","indications","adverse_reactions","contraindications","warnings","dosage"],"source":"OpenFDA Label"},{"id":2,"url":"https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:\"SILVER\"","fields":["approvals","company"],"source":"OpenFDA Drugs@FDA"},{"id":3,"url":"https://clinicaltrials.gov/search?intr=silver","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":4,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=silver","fields":["publications"],"source":"PubMed/NCBI"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-31T10:35:09.168711","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:11:51.769501+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"silver","indications":{"approved":[{"name":"second degree burns","source":"OpenFDA Label","regulator":"FDA"},{"name":"third degree burns","source":"OpenFDA Label","regulator":"FDA"},{"name":"wound sepsis","source":"OpenFDA Label","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"currentOwner":"King Pharms Llc","drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[],"trialDetails":[{"nctId":"NCT00964093","phase":"NA","title":"The Effectiveness of Silver Alginate (Algidex) Patch in the Prevention of Central Line Infections in Very Low Birth Weight Infants","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2008-11-23","conditions":["Central Line Bloodstream Infections"],"enrollment":100,"completionDate":"2015-08-20"},{"nctId":"NCT03713866","phase":"NA","title":"Peri-Procedural Transmural Electrophysiological (EP) Imaging of Scar-Related Ventricular Tachycardia","status":"RECRUITING","sponsor":"John Sapp","startDate":"2019-11-01","conditions":["Ventricular Tachycardia","Myocardial Infarction"],"enrollment":20,"completionDate":"2027-03-31"},{"nctId":"NCT01297400","phase":"PHASE2","title":"Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns","status":"RECRUITING","sponsor":"Skingenix, Inc.","startDate":"2022-03-11","conditions":["Burns"],"enrollment":60,"completionDate":"2026-12-31"},{"nctId":"NCT07322913","phase":"","title":"Intervascular Post-Market Clinical Follow-Up (PMCF) Registry","status":"RECRUITING","sponsor":"Intervascular","startDate":"2025-12-19","conditions":["Carotid Artery Diseases","Aortic Diseases","Peripheral Arterial Diseases"],"enrollment":1200,"completionDate":"2026-12"},{"nctId":"NCT06328010","phase":"","title":"Clinical Registry Collecting Real World Evidence on Wound Care Treatments","status":"ENROLLING_BY_INVITATION","sponsor":"Siddhey LLC","startDate":"2024-04-01","conditions":["Wounds and Injuries","Burns","Mohs Surgery","Diabetic Foot Ulcer Mixed","Venous Leg Ulcer","Non-healing Wound","Trauma Injury","Injury and Wounds","Degloving Injuries","Pressure Ulcers, Bedsores, Decubitus Ulcer"],"enrollment":5000,"completionDate":"2030-06-30"},{"nctId":"NCT05057429","phase":"NA","title":"A Bioelectric Dressing for Post De-Roofing Treatment of HS","status":"COMPLETED","sponsor":"University of Miami","startDate":"2021-10-11","conditions":["Hidradenitis Suppurativa"],"enrollment":12,"completionDate":"2024-05-15"},{"nctId":"NCT07455604","phase":"PHASE2","title":"Preventing Early Childhood Caries With a Silver Diamine Fluoride Gel","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2026-01-01","conditions":["Early Childhood Caries (ECC)"],"enrollment":1500,"completionDate":"2028-12-31"},{"nctId":"NCT06241261","phase":"PHASE2","title":"Arresting Early Childhood Caries With a Silver Diamine Fluoride Gel","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2024-01-01","conditions":["Early Childhood Caries"],"enrollment":630,"completionDate":"2027-12-31"},{"nctId":"NCT06831084","phase":"NA","title":"Acute Radiation Dermatitis After Adjuvant Radiotherapy for Breast Cancer Patients With the Use of Silver-Plated Technology","status":"ACTIVE_NOT_RECRUITING","sponsor":"Parul Barry","startDate":"2025-05-01","conditions":["Radiation Dermatitis Acute"],"enrollment":17,"completionDate":"2026-03-17"},{"nctId":"NCT07447583","phase":"NA","title":"Traditional vs. Minimally Invasive Decay Treatments in Primary Molars: An 18-month Split-mouth Randomized Study","status":"COMPLETED","sponsor":"TC Erciyes University","startDate":"2024-08-01","conditions":["Dental Caries"],"enrollment":60,"completionDate":"2026-02-09"},{"nctId":"NCT07265830","phase":"PHASE3","title":"Building Adaptive School-based Interventions for Caries","status":"NOT_YET_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2026-09","conditions":["Dental Caries"],"enrollment":1200,"completionDate":"2030-06"},{"nctId":"NCT06165042","phase":"NA","title":"Silver Diamine Fluoride in Molar-Incisor Hypomineralisation","status":"COMPLETED","sponsor":"Marmara University","startDate":"2023-04-01","conditions":["Molar-Incisor Hypomineralisation"],"enrollment":34,"completionDate":"2025-05-30"},{"nctId":"NCT07431463","phase":"NA","title":"Effects of Different Remineralization Agents on the Progression of Non-Cavitated Approximal Carious Lesions in Primary Teeth: A Randomized Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Izmir Katip Celebi University","startDate":"2025-10-01","conditions":["Dental Caries"],"enrollment":90,"completionDate":"2026-12-30"},{"nctId":"NCT06416462","phase":"NA","title":"Action of Photodynamic Therapy on Wound Quality and Tissue Repair in the Diabetic Foot","status":"COMPLETED","sponsor":"University of Nove de Julho","startDate":"2024-07-30","conditions":["Diabetic Foot Ulcer"],"enrollment":94,"completionDate":"2024-12-01"},{"nctId":"NCT07014722","phase":"NA","title":"Contact Activation of Coagulation in Newly Inserted Central Venous Catheters","status":"RECRUITING","sponsor":"Thomas Kander","startDate":"2025-09-10","conditions":["Central Venous Catheter","Coagulation","Coagulation Activation","Central Venous Catheter Complications"],"enrollment":88,"completionDate":"2026-12-30"},{"nctId":"NCT05163392","phase":"NA","title":"A Silver Lining in the VAD Sky","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2022-02-01","conditions":["LVAD (Left Ventricular Assist Device) Driveline Infection"],"enrollment":25,"completionDate":"2026-01-26"},{"nctId":"NCT07405437","phase":"","title":"General Dentists' Knowledge, Attitudes and Clinical Usage of SDF","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Edinburgh","startDate":"2025-03-03","conditions":["Decay, Dental"],"enrollment":34,"completionDate":"2026-03-31"},{"nctId":"NCT05964387","phase":"NA","title":"Effect of Silver Diamine Fluoride on Local Anesthesia in Hypomineralized Molars","status":"RECRUITING","sponsor":"University of Michigan","startDate":"2023-06-12","conditions":["Molar Incisor Hypomineralization","Anesthesia, Local"],"enrollment":50,"completionDate":"2027-12-31"},{"nctId":"NCT07384689","phase":"NA","title":"Microenvironment in Patients Undergoing Non-traumatic Amputation","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2025-08-01","conditions":["Lower Limb Amputation Above Knee"],"enrollment":20,"completionDate":"2028-01"},{"nctId":"NCT07397572","phase":"","title":"Iron Supplementation and Anemia After Sleeve Gastrectomy","status":"RECRUITING","sponsor":"Cairo University","startDate":"2026-01-17","conditions":["Iron Deficiency Anemia","Obesity","Sleeve Gastrectomy"],"enrollment":66,"completionDate":"2027-01"},{"nctId":"NCT07391748","phase":"EARLY_PHASE1","title":"Efficacy of a Polyhexanide Biguanide-Based Gel in the Prevention of Biofilm Formation in Pressure Ulcers","status":"NOT_YET_RECRUITING","sponsor":"Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana","startDate":"2026-01-30","conditions":["Pressure Ulcers","Pressure Ulcers Stage III","Pressure Ulcer Prevention","Pressure Ulcer ( Stage 2-3)","Biofilm Formation","Biofilm","Biofilm Removal"],"enrollment":140,"completionDate":"2026-09-30"},{"nctId":"NCT07250009","phase":"NA","title":"Effect of Silver Diamine Fluoride and LED Activation on Residual Caries Activity in Class II Cavities","status":"COMPLETED","sponsor":"Çanakkale Onsekiz Mart University","startDate":"2025-12-10","conditions":["Dental Caries"],"enrollment":40,"completionDate":"2026-01-30"},{"nctId":"NCT07392294","phase":"NA","title":"Foam Dressing Versus Silver Foam Dressing for Pediatric Tracheostomy Wound Care","status":"COMPLETED","sponsor":"Acibadem Atasehir Hospital","startDate":"2022-03-01","conditions":["Tracheostomy Complication","Pressure Ulcer (PU)","Surgical Wound"],"enrollment":50,"completionDate":"2024-08-30"},{"nctId":"NCT07300137","phase":"NA","title":"Comparison of Amniotic Membrane Dressing and Aquacel®Ag in Second-degree Burns","status":"ENROLLING_BY_INVITATION","sponsor":"Patel Hospital, Pakistan","startDate":"2025-09-20","conditions":["Second Degree Burns"],"enrollment":100,"completionDate":"2026-08-01"},{"nctId":"NCT02821741","phase":"NA","title":"Effects of External Ear Stimulation on Pain Perception and Mood","status":"RECRUITING","sponsor":"National Center for Complementary and Integrative Health (NCCIH)","startDate":"2016-10-18","conditions":["Pain in Healthy Participants"],"enrollment":76,"completionDate":"2026-03-30"},{"nctId":"NCT07382245","phase":"NA","title":"Efficacy of Silver Diamine Fluoride Versus Nano-Silver Fluoride in Arresting Active Dentin Caries in Primary Teeth in Young Children","status":"NOT_YET_RECRUITING","sponsor":"October University for Modern Sciences and Arts","startDate":"2026-01-30","conditions":["Early Childhood Caries (ECC)","Active Dentin Caries in Primary Molars"],"enrollment":60,"completionDate":"2026-03-15"},{"nctId":"NCT07066254","phase":"NA","title":"The Mepilex Cesarean Delivery Trial","status":"NOT_YET_RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2026-02","conditions":["Surgical Site Infection Following Cesarean Delivery"],"enrollment":480,"completionDate":"2026-12"},{"nctId":"NCT07342049","phase":"NA","title":"ConvaVAC™ Ag+ Negative Pressure Wound Therapy System in Chronic Wounds","status":"NOT_YET_RECRUITING","sponsor":"ConvaTec Inc.","startDate":"2026-01-12","conditions":["Venous Leg Ulcer (VLU)"],"enrollment":87,"completionDate":"2026-10-01"},{"nctId":"NCT07371117","phase":"PHASE2","title":"Effect Of Silverdiamine Fluoride Gel, Sodium Fluoride With CPP-ACP, APF On Early Childhood Caries - A Randomised Controlled Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Jazan","startDate":"2025-11-01","conditions":["Early Childhood Caries (ECC)","Dental Caries"],"enrollment":90,"completionDate":"2026-02"},{"nctId":"NCT07366645","phase":"NA","title":"Clinical and Cost-Effectiveness of Silver Diamine Fluoride and Silver Fluoride, With or Without Application of LED, in Arresting Incipient Permament Molar Caries","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-03-01","conditions":["Incipient Caries"],"enrollment":366,"completionDate":"2027-07-01"},{"nctId":"NCT07367087","phase":"NA","title":"Silver Sulfadiazine With Hyaluronic Acid Versus Silver Sulfadiazine Alone in Partial-Thickness Burns","status":"NOT_YET_RECRUITING","sponsor":"Dr Muhammad Naveed Shahzad","startDate":"2026-02","conditions":["Partial-Thickness Burn, Thermal Burn"],"enrollment":30,"completionDate":"2026-10"},{"nctId":"NCT00659204","phase":"PHASE3","title":"Efficacy of Silver Nanoparticle Gel Versus a Common Antibacterial Hand Gel","status":"TERMINATED","sponsor":"Madigan Army Medical Center","startDate":"2008-01","conditions":["Healthy"],"enrollment":22,"completionDate":"2008-08"},{"nctId":"NCT07337616","phase":"NA","title":"Field Shield Wound Dressing Study","status":"RECRUITING","sponsor":"KeriCure Medical","startDate":"2025-05-01","conditions":["Burn Wounds - Partial Thickness (2nd Degree)"],"enrollment":40,"completionDate":"2026-09-29"},{"nctId":"NCT06737809","phase":"NA","title":"IP-coated Revision Hip Implants","status":"RECRUITING","sponsor":"Aesculap AG","startDate":"2025-06-25","conditions":["Peri-Prosthetic Joint Infection"],"enrollment":268,"completionDate":"2028-06"},{"nctId":"NCT06258889","phase":"NA","title":"Optimizing Exposure Therapy Via Reward-focused Interventions in Individuals With Public Speaking Anxiety","status":"COMPLETED","sponsor":"Philipps University Marburg","startDate":"2024-01-08","conditions":["Public Speaking Fear"],"enrollment":40,"completionDate":"2024-12-13"},{"nctId":"NCT07326241","phase":"NA","title":"Effects of Silver Diamine Fluoride and Intraoral Cryotherapy on Local Anesthesia in MIH-Affected Molars","status":"NOT_YET_RECRUITING","sponsor":"Çanakkale Onsekiz Mart University","startDate":"2026-02-01","conditions":["MIH","Molar-Incisor Hypomineralization","Caries Assessment"],"enrollment":75,"completionDate":"2026-04-01"},{"nctId":"NCT07308353","phase":"NA","title":"Comparative Effects Of Exergaming And Otago Exercise On Anticipatory Postural Control And Sensory Integration In Older Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Foundation University Islamabad","startDate":"2025-11-18","conditions":["Exergaming","Exercise Therapy","Frail Elderly","Healthy Aging","Mobility Limitation","Muscle Strength","Postural Balance","Proprioception"],"enrollment":36,"completionDate":"2026-07-01"},{"nctId":"NCT01698203","phase":"PHASE4","title":"Continuous Wound Catheter Analgesia Associated With Intravenous Morphine PCA After Thoracotomy","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2012-10-14","conditions":["Pain","Thoracotomy"],"enrollment":92,"completionDate":"2018-10-11"},{"nctId":"NCT06349083","phase":"PHASE2","title":"Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-08-26","conditions":["Alcohol Use Disorder"],"enrollment":200,"completionDate":"2029-05"},{"nctId":"NCT06786975","phase":"NA","title":"Effectiveness and Acceptability of SDF Compared to ART for the Management of Early Childhood Caries","status":"NOT_YET_RECRUITING","sponsor":"Universidad de La Frontera","startDate":"2025-12-15","conditions":["Early Childhood Caries","Health Care Acceptability"],"enrollment":156,"completionDate":"2027-02-28"},{"nctId":"NCT07221526","phase":"","title":"SPO2 VALIDATION STUDY - PHILIPS FAST 2025","status":"RECRUITING","sponsor":"Philips Clinical & Medical Affairs Global","startDate":"2025-10-28","conditions":["PULSE OXIMETRY"],"enrollment":72,"completionDate":"2026-01-09"},{"nctId":"NCT02649894","phase":"NA","title":"Safety and Effectiveness of a New Pleural Catheter for Symptomatic, Recurrent, MPEs Versus Approved Pleural Catheter","status":"COMPLETED","sponsor":"C. R. Bard","startDate":"2016-05","conditions":["Malignant Pleural Effusion"],"enrollment":119,"completionDate":"2018-04-18"},{"nctId":"NCT07249450","phase":"NA","title":"Comparison of Sonic and Ultrasonic Activation on Healing of Apical Periodontitis","status":"COMPLETED","sponsor":"Hilal Çuhadar Beşiroğlu","startDate":"2023-03-01","conditions":["Apical Periodontitis"],"enrollment":42,"completionDate":"2025-03-12"},{"nctId":"NCT05690685","phase":"NA","title":"PMS Study of Silver I Alginate Non-Woven Dressing (Hydro-Alginate)","status":"COMPLETED","sponsor":"Advanced Medical Solutions Ltd.","startDate":"2023-05-16","conditions":["Wound"],"enrollment":56,"completionDate":"2025-07-31"},{"nctId":"NCT05045430","phase":"NA","title":"PMS Study to Confirm the Ongoing Safety and Performance of Silver II Non-woven Dressing in Chronic and Acute Wounds","status":"COMPLETED","sponsor":"Advanced Medical Solutions Ltd.","startDate":"2022-07-13","conditions":["Wound"],"enrollment":240,"completionDate":"2025-09-30"},{"nctId":"NCT05845112","phase":"","title":"Start Taking Action For TB Diagnosis","status":"COMPLETED","sponsor":"Liverpool School of Tropical Medicine","startDate":"2025-02-28","conditions":["Diagnosis","Tuberculosis"],"enrollment":14747,"completionDate":"2025-03-28"},{"nctId":"NCT07147400","phase":"PHASE2","title":"Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults","status":"RECRUITING","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2025-08-22","conditions":["Prevention of Malaria Transmission and Clinical Malaria"],"enrollment":1200,"completionDate":"2027-11"},{"nctId":"NCT07181967","phase":"NA","title":"SDF vs Fluoride Varnish for Streptococcus Mutans Reduction in Children","status":"RECRUITING","sponsor":"Assiut University","startDate":"2025-09-15","conditions":["Dental Caries"],"enrollment":48,"completionDate":"2025-12-30"},{"nctId":"NCT07213661","phase":"NA","title":"LT Comparative Effectiveness of 2 Caries Treatments","status":"RECRUITING","sponsor":"Case Western Reserve University","startDate":"2025-10-08","conditions":["Dental Caries"],"enrollment":480,"completionDate":"2030-01"},{"nctId":"NCT06601933","phase":"PHASE2","title":"Cognitive Training and Neuroplasticity in Mild Cognitive Impairment: COGIT-2 Trial","status":"RECRUITING","sponsor":"Columbia University","startDate":"2024-12-17","conditions":["Mild Cognitive Impairment (MCI)","Cognitive Training"],"enrollment":240,"completionDate":"2029-02-28"},{"nctId":"NCT05495984","phase":"NA","title":"Neuroplasticity in Maternal Opioid Use Disorder (OUD)","status":"RECRUITING","sponsor":"Yale University","startDate":"2023-01-01","conditions":["Opioid Use Disorder"],"enrollment":15,"completionDate":"2026-06"},{"nctId":"NCT05971173","phase":"EARLY_PHASE1","title":"Nutritional Optimization and Bone Health Management for Older Adults Undergoing Hip Fracture Surgery","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2023-09-28","conditions":["Hip Fractures"],"enrollment":40,"completionDate":"2025-06-04"},{"nctId":"NCT07215429","phase":"","title":"SpO2 Validation Study-Philips Optimus","status":"COMPLETED","sponsor":"Philips Clinical & Medical Affairs Global","startDate":"2025-09-09","conditions":["Pulse Oximetry, Oxygen Measurements, SpO2"],"enrollment":24,"completionDate":"2025-09-19"},{"nctId":"NCT06926322","phase":"NA","title":"Evaluation of Different Medicaments in the Management of Necrotic Primary Molars by Lesion Sterilization and Tissue Repair","status":"ENROLLING_BY_INVITATION","sponsor":"Ain Shams University","startDate":"2025-10","conditions":["Pain, Postoperative","Root Resorption","Persistent Infection","Necrotic Pulp"],"enrollment":108,"completionDate":"2030-08"},{"nctId":"NCT06361667","phase":"NA","title":"Culture and Well-being: Art as Prescription Therapy (\"Art on Prescription\")","status":"COMPLETED","sponsor":"KAVADIA ELENI","startDate":"2024-03-20","conditions":["Mental Health Issue","Anxiety Disorders","Depressive Disorder","Emotional Disorder","Schizophrenia","Autism"],"enrollment":382,"completionDate":"2024-12-19"},{"nctId":"NCT07200063","phase":"NA","title":"Children Acceptance of AgNP Mouthwash Against Chlorhexidine Mouthwash","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-01","conditions":["Teeth Staining","Numbness of the Tongue and Soft Tissue","Bitter Taste"],"enrollment":60,"completionDate":"2026-06"},{"nctId":"NCT06121479","phase":"PHASE3","title":"Oral Branched-chain Amino Acid Supplementation for Decompensated Cirrhotic Patients","status":"ENROLLING_BY_INVITATION","sponsor":"Mahidol University","startDate":"2023-11-13","conditions":["Decompensated Cirrhosis and Ascites"],"enrollment":30,"completionDate":"2025-12-31"},{"nctId":"NCT07194629","phase":"PHASE4","title":"Pilot and Feasibility Study of Impact of SDF 38% Application on Oral Health of Elderly With Autonomy Loss","status":"NOT_YET_RECRUITING","sponsor":"Université de Montréal","startDate":"2025-10-01","conditions":["Dental Caries","Elderly","Loss of Autonomy","Silver Diamine Fluoride"],"enrollment":60,"completionDate":"2026-12-31"},{"nctId":"NCT05765058","phase":"NA","title":"The Efficacy of Tooth Mouse, SFD and NaF in Caries Activity in Root Caries. A Randomized Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"University of Bern","startDate":"2026-02-01","conditions":["Root Caries","NaF","SDF","Tooth Mousse"],"enrollment":136,"completionDate":"2027-06-28"},{"nctId":"NCT07189143","phase":"NA","title":"Silver Fir Safety in Healthy Volunteers","status":"COMPLETED","sponsor":"University of Ljubljana","startDate":"2018-08-20","conditions":["Safety / Toxicology","Liver Function","Kidney Function","Dietary Supplement","Healthy Volunteers"],"enrollment":15,"completionDate":"2018-10-29"},{"nctId":"NCT05260463","phase":"NA","title":"LOQTEQ® Antibacterial Pre-Market Study","status":"COMPLETED","sponsor":"aap Implantate AG","startDate":"2021-12-09","conditions":["Fractures, Open","Fractures, Closed","Surgical Site Infection","Fracture of Fibula"],"enrollment":203,"completionDate":"2025-08-04"},{"nctId":"NCT05403125","phase":"EARLY_PHASE1","title":"SDF Application in Oral Cancer Patients to Prevent Dental Caries","status":"COMPLETED","sponsor":"Texas A & M University Baylor College Of Dentistry","startDate":"2022-05-20","conditions":["Dental Caries"],"enrollment":56,"completionDate":"2025-03-18"},{"nctId":"NCT06523491","phase":"","title":"Intra-articular Polyacrylamide Hydrogel in the Treatment of Knee Osteoarthritis","status":"COMPLETED","sponsor":"Research Centre BIOFORM","startDate":"2022-05-07","conditions":["Osteoarthritis, Knee"],"enrollment":57,"completionDate":"2024-05-18"},{"nctId":"NCT01552226","phase":"NA","title":"Compare Preperitoneal Analgesia to Epidural Analgesia for Pain Control After Colon and Rectal Surgery","status":"COMPLETED","sponsor":"Trinity Health Michigan","startDate":"2010-01","conditions":["Colon Cancer","Rectal Cancer","Colonic Diverticulosis"],"enrollment":98,"completionDate":"2015-03"},{"nctId":"NCT07149844","phase":"EARLY_PHASE1","title":"Healing Effect of Tea Tree Oil on Burn","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2021-07-02","conditions":["Burn"],"enrollment":30,"completionDate":"2023-09-22"},{"nctId":"NCT07147790","phase":"","title":"Comparative Study of Negative-Pressure Wound Therapy Integrated With Silver Nanoparticle Spray Versus Negative-Pressure Wound Therapy in Post-Revascularization Diabetic Foot Wound Management","status":"ENROLLING_BY_INVITATION","sponsor":"Kafrelsheikh University","startDate":"2024-05-05","conditions":["Ischemia Limb","Diabete Mellitus"],"enrollment":100,"completionDate":"2025-12-10"},{"nctId":"NCT05824026","phase":"NA","title":"Investigation of the Clinical Performance of Biatain Fiber Ag on Burns","status":"COMPLETED","sponsor":"Coloplast A/S","startDate":"2023-10-27","conditions":["Partial-thickness Burn"],"enrollment":52,"completionDate":"2024-04-26"},{"nctId":"NCT07150585","phase":"NA","title":"Effects of Irrigation Activation Systems on Postoperative Pain and Lesion Healing in Single-Visit Retreatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ege University","startDate":"2024-08-01","conditions":["Retreatment","Asymptomatic Apical Periodontitis"],"enrollment":75,"completionDate":"2027-06-01"},{"nctId":"NCT04074356","phase":"NA","title":"Non-invasive Markers of Esophageal Function in Adults","status":"ENROLLING_BY_INVITATION","sponsor":"Vanderbilt University Medical Center","startDate":"2019-09-04","conditions":["Dysphagia"],"enrollment":90,"completionDate":"2026-09"},{"nctId":"NCT06987981","phase":"NA","title":"Comparing How Burn Wounds and Scars Heal in Children Using Chitosan and Silver Dressings","status":"RECRUITING","sponsor":"Miloš Potkonjak","startDate":"2025-07-21","conditions":["Burns Degree Second","Pediatric"],"enrollment":40,"completionDate":"2027-09-30"},{"nctId":"NCT07153328","phase":"NA","title":"SDF With or Without Fluoride Varnish for Caries Arrest in Primary Teeth of Young Children","status":"COMPLETED","sponsor":"Beaty Dent","startDate":"2021-01-07","conditions":["Dental Caries"],"enrollment":104,"completionDate":"2024-03-25"},{"nctId":"NCT06547138","phase":"","title":"Pilot Study on the Effectiveness and Safety of OPTILENE® SILVER MESH ELASTIC in Prevention of Surgical Site Infection (SSI) and Incisional Hernia (IH)","status":"NOT_YET_RECRUITING","sponsor":"Aesculap AG","startDate":"2026-03","conditions":["Abdominal Aortic Aneurysm","Morbid Obesity"],"enrollment":110,"completionDate":"2029-12"},{"nctId":"NCT03621592","phase":"NA","title":"VLU Dressing Study","status":"COMPLETED","sponsor":"University of Miami","startDate":"2018-08-22","conditions":["Venous Leg Ulcer"],"enrollment":31,"completionDate":"2023-11-01"},{"nctId":"NCT06042283","phase":"NA","title":"Efficacy of Metacognitive Training in Older Adults With Depression","status":"COMPLETED","sponsor":"Istanbul University - Cerrahpasa","startDate":"2023-09-15","conditions":["Depression in Old Age"],"enrollment":50,"completionDate":"2024-10-30"},{"nctId":"NCT07136233","phase":"NA","title":"Impact of Benefit Inserts on Health Plan Selection and Utilization Among Renewing Covered California Members","status":"ACTIVE_NOT_RECRUITING","sponsor":"Covered California","startDate":"2024-10-04","conditions":["Outreach Intervention"],"enrollment":1600000,"completionDate":"2026-07-30"},{"nctId":"NCT07125937","phase":"NA","title":"Silver Diamine Flouride in Arresting Enamel Caries","status":"COMPLETED","sponsor":"HITEC-Institute of Medical Sciences","startDate":"2024-05-07","conditions":["Carious Lesion"],"enrollment":250,"completionDate":"2025-05-07"},{"nctId":"NCT03916926","phase":"NA","title":"Older Adult Effectiveness of 2 Treatments","status":"COMPLETED","sponsor":"Case Western Reserve University","startDate":"2019-09-18","conditions":["Dental Caries"],"enrollment":568,"completionDate":"2024-06-07"},{"nctId":"NCT06645860","phase":"NA","title":"SMART With Different Modifications in Asymptomatic Deep Carious Lesions of Primary Molars.","status":"RECRUITING","sponsor":"Çanakkale Onsekiz Mart University","startDate":"2025-01-01","conditions":["Caries; Dentin"],"enrollment":150,"completionDate":"2026-01-01"},{"nctId":"NCT05625828","phase":"NA","title":"Evaluation of the Effects of a Cognitive-Motor Fall Prevention Program on Fall Risk Factors","status":"ACTIVE_NOT_RECRUITING","sponsor":"EZUS-LYON 1","startDate":"2022-09-13","conditions":["Accidental Falls","Aging","Mild Cognitive Impairment"],"enrollment":176,"completionDate":"2025-10-24"},{"nctId":"NCT03472664","phase":"NA","title":"Brain Energy for Amyloid Transformation in Alzheimer's Disease Study","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2018-07-16","conditions":["Alzheimer Disease","Mild Cognitive Impairment"],"enrollment":120,"completionDate":"2026-04"},{"nctId":"NCT07085689","phase":"NA","title":"Evaluation of the Effectiveness of Various Desensitizing Treatment Protocols","status":"COMPLETED","sponsor":"Hacettepe University","startDate":"2023-04-20","conditions":["Molar Incisor Hypomineralization"],"enrollment":52,"completionDate":"2025-05-09"},{"nctId":"NCT03012048","phase":"NA","title":"Effectiveness of Point-of-use Water Treatment Technologies to Prevent Stunting Among Children in South Africa","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2016-06","conditions":["Diarrhoea;Infectious;Presumed","Diarrhea, Infantile","Diarrhea Tropical","Environmental Exposure","Enteropathy","Malnutrition, Child"],"enrollment":415,"completionDate":"2020-12"},{"nctId":"NCT06872151","phase":"PHASE4","title":"Evaluation of the Effectiveness of a Topical Medical Device in Wound Healing and Symptom Relief in the Postoperative Period of Open Excisional Hemorrhoidectomy (The Emor Study)","status":"COMPLETED","sponsor":"University of Cagliari","startDate":"2025-03-04","conditions":["Anus Diseases","Gastrointestinal Diseases","Intestinal Diseases","Cicatrization","Hemorrhoids","Hemorrhoids Third Degree"],"enrollment":114,"completionDate":"2025-05-30"},{"nctId":"NCT05347654","phase":"NA","title":"Evaluation of a Management Strategy for Second-degree Fibrinous Burns Integrating a Poly-absorbent Dressing","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2023-01-20","conditions":["Burns Degree Second"],"enrollment":7,"completionDate":"2025-04-29"},{"nctId":"NCT07023939","phase":"PHASE4","title":"Atraumatic Versus Silver-Modified Atraumatic Restorative Treatment in Primary Molars","status":"COMPLETED","sponsor":"Beirut Arab University","startDate":"2023-05-02","conditions":["Dental Caries","Dental Caries in Children"],"enrollment":34,"completionDate":"2024-12-10"},{"nctId":"NCT03304587","phase":"NA","title":"Effects of Bright Light on Co-occurring Cancer-related Symptoms in Breast Cancer Survivors","status":"COMPLETED","sponsor":"Michigan State University","startDate":"2017-11-06","conditions":["Breast Cancer"],"enrollment":30,"completionDate":"2022-08-31"},{"nctId":"NCT03004807","phase":"NA","title":"Role of Centrum® Silver® in Improving Micronutrient Status in Older Men","status":"COMPLETED","sponsor":"Oregon State University","startDate":"2018-07-01","conditions":["Vitamin Deficiency","Mineral Deficiency","Aging"],"enrollment":41,"completionDate":"2021-12-31"},{"nctId":"NCT07008040","phase":"NA","title":"Assessing the Effect of the Silver Dressing on Surgical Site Infections in Adult Patients Post Cardiac Surgery: a Single Center Randomized Control Trial","status":"ENROLLING_BY_INVITATION","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2025-06-30","conditions":["Surgical Site Infection After Major Surgery","Surgical Site Infections"],"enrollment":145,"completionDate":"2026-12-31"},{"nctId":"NCT05873257","phase":"NA","title":"Investigation of the Clinical Performance of Biatain Fiber Ag on Venous Leg Ulcers","status":"COMPLETED","sponsor":"Coloplast A/S","startDate":"2023-07-31","conditions":["Venous Leg Ulcer"],"enrollment":50,"completionDate":"2024-05-17"},{"nctId":"NCT05736484","phase":"NA","title":"Randomized Clinical Trial to Improve Mobility After Hospitalization","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2023-09-19","conditions":["Hypertension","Diabetes","Heart Failure","Ambulatory Difficulty","Mobility Limitation"],"enrollment":350,"completionDate":"2025-12-31"},{"nctId":"NCT06629558","phase":"NA","title":"Bronchoscopic Lung Volume Reduction in Management of Localized Emphysema","status":"RECRUITING","sponsor":"Mansoura University Hospital","startDate":"2024-10-01","conditions":["Bronchoscopic Lung Volume Reduction"],"enrollment":30,"completionDate":"2026-03-01"},{"nctId":"NCT06970236","phase":"NA","title":"Resistance Exercise in Patients With Ocular Melanoma","status":"RECRUITING","sponsor":"University of Valencia","startDate":"2025-02-01","conditions":["Ocular Melanoma"],"enrollment":40,"completionDate":"2026-12"},{"nctId":"NCT05923749","phase":"NA","title":"A RCT Evaluating the Clinical Benefit of a Silver Dressing in the Treatment of Venous Leg Ulcers","status":"COMPLETED","sponsor":"Coloplast A/S","startDate":"2023-06-29","conditions":["Wound Heal"],"enrollment":180,"completionDate":"2025-01-29"},{"nctId":"NCT06616844","phase":"NA","title":"IDEAL: Efficacy of Porcine Placental Extracellular Matrix Augmented Plus Standard of Care (SOC) Versus SOC Alone for the Management of Diabetic Foot Ulcers","status":"RECRUITING","sponsor":"ConvaTec Inc.","startDate":"2025-02-12","conditions":["Wound Heal","Ulcer"],"enrollment":194,"completionDate":"2026-07"},{"nctId":"NCT05748067","phase":"NA","title":"Minimally Invasive Treatment for Permanent Molars Affected With Molar-incisor Hypomineralization Defects","status":"COMPLETED","sponsor":"King Abdullah University Hospital","startDate":"2021-11-29","conditions":["Molar Incisor Hypomineralization"],"enrollment":73,"completionDate":"2025-05-01"},{"nctId":"NCT06446076","phase":"NA","title":"Feedback Using behaviOral econOmic Theories on STEP countS in Cardiovascular Disease Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Luke's International Hospital, Japan","startDate":"2024-06-12","conditions":["Cardiovascular Diseases","Rehabilitation","Behavioral Economics"],"enrollment":325,"completionDate":"2026-03-31"},{"nctId":"NCT06971562","phase":"NA","title":"Silver in Partial Thickness Pediatric Burns","status":"ACTIVE_NOT_RECRUITING","sponsor":"IWK Health Centre","startDate":"2017-05-03","conditions":["Pediatric Burns"],"enrollment":80,"completionDate":"2025-05-10"},{"nctId":"NCT06963788","phase":"PHASE3","title":"The Comparative Effects of Using 0.12% Chlorhexidine and Silver Nanoparticles Mouthwashes in Medical Students","status":"COMPLETED","sponsor":"Can Tho University of Medicine and Pharmacy","startDate":"2024-02-06","conditions":["Dental Plaque and Gingivitis"],"enrollment":95,"completionDate":"2024-12-31"},{"nctId":"NCT04689009","phase":"NA","title":"Leg Ulcers Standards of Care Enhancement","status":"COMPLETED","sponsor":"Emoled","startDate":"2019-05-14","conditions":["Venous Leg Ulcer","Mixed Leg Ulcer"],"enrollment":83,"completionDate":"2024-02-29"},{"nctId":"NCT06412731","phase":"NA","title":"Comparing the Effectiveness of Papain Based Chemico-mechanical Caries Removal Gel and 38% Silver Diamine Fluoride for Treating Active Caries Lesion of Primary Molars","status":"COMPLETED","sponsor":"Al-Mustansiriyah University","startDate":"2024-01-02","conditions":["Dental Caries in Children"],"enrollment":45,"completionDate":"2024-07-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Topical","formulation":"Cream","formulations":[{"form":"CREAM","route":"TOPICAL","productName":""}]},"_patentsChecked":true,"crossReferences":{"UNII":"W46JY43EJR","RXCUI":"106351","SPL_ID":"f63c800f-63a1-498e-9814-28b41de0c3b2","chemblId":"CHEMBL177367"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"1990-","companyName":"Thepharmanetwork Llc","relationship":"Original Developer"},{"period":"present","companyName":"King Pharms Llc","relationship":"Current Owner"}],"publicationCount":95997,"therapeuticAreas":["Infectious Disease"],"applicationNumber":"NDA018810","biosimilarFilings":[],"originalDeveloper":"Thepharmanetwork Llc","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"active","companyName":"King Pharms Llc","companyId":"king-pharms-llc","modality":"Small molecule","firstApprovalDate":"1990","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1982-09-15T00:00:00.000Z","mah":"KING PHARMS LLC","brand_name_local":null,"application_number":"NDA017381"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1986-11-17T00:00:00.000Z","mah":"THEPHARMANETWORK LLC","brand_name_local":null,"application_number":"NDA018810"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1989-03-15T00:00:00.000Z","mah":"DR REDDYS","brand_name_local":null,"application_number":"NDA018578"},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":"THEPHARMANETWORK LLC","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":null,"mah":"THEPHARMANETWORK LLC","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":"THEPHARMANETWORK LLC","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":"THEPHARMANETWORK LLC","brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"THEPHARMANETWORK LLC","brand_name_local":null,"application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":"THEPHARMANETWORK LLC","brand_name_local":null,"application_number":null}],"trialStats":{"total":19,"withResults":2},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:11:51.769501+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}